
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc has demonstrated a positive financial trajectory, with third-quarter revenue exceeding consensus expectations and management raising gross margin guidance for 2025 to 76-77%, indicating a strong outlook for profitability. The company's commitment to a strategic approach in light adjustable lens (LAL) placements is expected to enhance utilization rates across an expanding installed base, which supports sustained double-digit growth. Additionally, despite increased operating expenses, RxSight's proactive management indicates confidence in achieving operational efficiency and financial performance improvements moving forward.
Bears say
RxSight Inc has experienced a significant decline in its operational metrics, with monthly utilization of light adjustable lenses (LALs) decreasing to 8.0 units per laser delivery device (LDD) in 3Q25, down from 8.7 in the preceding quarter and 10.1 a year prior. The company reported revenue of $30.3 million for the period, reflecting a 14% year-over-year decrease, alongside a sharp decline in LDD placements which fell by 68% year-over-year and 38% quarter-over-quarter to just 25 units in 2Q25. Additional risks impacting the company's outlook include limited market adoption due to the need for specialized capital equipment, challenges in commercial execution, increasing competition within the intraocular lens market, and potential financing that could dilute shareholder value.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares